Effective treatment of SARS-CoV-2-infected rhesus macaques by attenuating inflammation
Autor
Lu, Shuaiyao
Zhao, Jingjing
Dong, Jiebin
Liu, Hongqi
Zhu, Yinhua
Li, Honggang
Liu, Liping
Yang, Yun
Sun, Shicheng
Song, Yifan
Zhao, Yuan
She, Ruiping
Luo, Tuoping
Deng, Hongkui
Peng, Xiaozhong
Institución
Resumen
The COVID-19 pandemic caused by the SARS-CoV-2 virus has
caused a significant public health crisis worldwide. Recent studies
show that excessive inflammatory response is critical for SARSCoV-2 pathogenesis and COVID-19 severity,1 which can lead to
acute lung injury (ALI) and acute respiratory distress syndrome
(ARDS).2 One major factor for acute inflammation in SARS-CoV-2
infection is the inflammatory macrophages, which has been
considered important for the production of large amounts of
proinflammatory cytokines.3 Autopsy identified an intense infiltration of macrophages in the lung tissues of fatal COVID-19
patients.4 Furthermore, single-cell RNA sequencing (scRNA-seq)
showed a higher proportion of macrophages presenting in
bronchoalveolar lavage fluid (BALF) of severe COVID-19 patients.5
Consistent with studies of SARS-CoV-2, infiltration and accumulation of macrophages in the lung were also found in other
coronavirus diseases.6 Depletion of macrophages protected mice
from lethal SARS-CoV infection, highlighting the important roles of
macrophages in coronavirus-induced symptoms.7 Therefore,
targeting macrophages to regulate hyperinflammation in SARSCoV-2 infection could be an effective strategy to treat COVID-19
patients.